$3.12-0.11 (-3.41%)
Ardelyx, Inc.
Ardelyx, Inc. in the Healthcare sector is trading at $3.12 with a market capitalization of $976M. Wall Street consensus targets $12.90 (10 analysts), implying a +313.5% move over the next 12 months. The stock is currently near its 52-week low of $3.09, remaining 43.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $120.88Mβ | $94.47Mβ | $125.22Mβ | $110.33Mβ | $97.66M |
| Gross Profit | $115.12Mβ | $89.66Mβ | $114.37Mβ | $106.35Mβ | $85.26M |
| Operating Income | -$12.43Mβ | -$32.79Mβ | $5.10Mβ | $4.67Mβ | -$14.39M |
| Net Income | -$16.72Mβ | -$37.60Mβ | -$407,000β | -$969,000β | -$19.08M |
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritabl...